Drug and asset intelligence for X-linked Retinitis with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Stage: Development stage unavailable

Mechanism of action

Gene Therapy

Recent signals(1)

ClinicalAugust 11, 2026

Gene Therapy Trial for X-linked Retinitis Pigmentosa Using AAV5-hRKp.RPGR Vector

A clinical trial is currently underway for the AAV5-hRKp.RPGR vector, targeting participants with X-linked retinitis pigmentosa (XLRP) associated with variants in the RPGR gene.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Therapeutic areas

Gene Therapy →

Ophthalmology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.